Recent Publications
Chronic angina costs more than you think
Summary
Angina significantly impacts patients’ quality of life and poses a growing economic burden on health systems worldwide. This analysis highlights the real cost of angina—from frequent doctor visits and emergency care to missed workdays and reduced productivity. Despite existing treatments, many patients still experience symptoms, underlining the unmet medical need. By improving disease management and treatment outcomes, we can reduce costs and enhance patient well-being.
If you want to learn more click hereAbout chronic stable angina
Chronic stable angina pectoris is a type of angina that is characterised by recurring chest pain or discomfort. It occurs when there is reduced blood flow to the heart muscle due to narrowed or blocked coronary arteries. The chest pain in chronic stable angina is usually triggered by physical exertion or emotional stress and typically lasts for a few minutes.
GlobalData estimates that sales of the angina market (stable, microvascular, variant) to be approximately $7.8bn across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) in 2028. GlobalData is the parent company of the Clinical Trials Arena.
About Auxilius Pharma
Auxilius Pharma is a privately held pharmaceutical company that commenced operations in 2019. Auxilius operates in the space of value-added medicines and brings innovation to areas of high unmet need for patients with diseases such as chronic stable angina pectoris that aim to impact public health positively. Auxilius Pharma’s R&D Strategy is driven by patients' need for affordable medications to manage their chronic conditions in the US and on other major markets.